Published in Hepatitis Weekly, September 3rd, 2001
V. Schmitz and coworkers at the University of Navarra in Pamplona explained that "unresectable hepatocellular carcinoma (HCC) lacks effective therapy and entails very poor prognosis." In an attempt to improve the prognosis, they developed a method to enhance antitumor immunity by overexpressing the T cell costimulatory molecule CD40 ligand (CD40L).
In vitro, adenovirus-mediated transfection of rat HCC cells resulted in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.